首页 > 最新文献

Journal of the Neurological Sciences最新文献

英文 中文
Comparative outcomes of endovascular vs. surgical treatment in craniocervical junction dural arteriovenous fistulas: A systematic review and meta-analysis.
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-21 DOI: 10.1016/j.jns.2025.123402
Basel Musmar, Joanna M Roy, Atakan Orscelik, Sravanthi Koduri, Spyridon Karadimas, Saman Sizdahkhani, Elias Atallah, Stavropoula I Tjoumakaris, Michael Reid Gooch, Hekmat Zarzour, Ritam Ghosh, Richard F Schmidt, Robert H Rosenwasser, Pascal Jabbour

Background: Craniocervical junction dural arteriovenous fistulas (CCJ-DAVFs) are rare and complex vascular malformations that are challenging to diagnose and treat. This study aims to compare surgical and endovascular treatments for CCJ-DAVFs through a systematic review and meta-analysis.

Methods: A systematic review and meta-analysis was conducted according to the PRISMA guidelines. PubMed, Scopus, and Web of Science databases were searched from inception to July 2024.

Results: Fifteen studies involving 266 patients were included. Of these, 143 (53.8 %) patients underwent surgical treatment alone and 123 (46.2 %) underwent endovascular treatment alone. In the surgical group, the complete obliteration rate at last follow-up was 89.8 %. Retreatment rate was 6.2 %. Periprocedural complications occurred in 21.6 % of cases. In the endovascular group, the complete occlusion rate at last follow-up was 73.6 %. Retreatment rate was 46.7 %. Periprocedural complications occurred in 18.8 % of cases. Comparative meta-analysis revealed that the rate of complete obliteration at last follow-up was significantly higher in the surgical group (OR: 0.24; CI: 0.07 to 0.89, p = 0.03). Surgical treatment had a significantly higher successful treatment rate (OR: 0.24; CI: 0.07 to 0.89, p = 0.03) and lower retreatment rate (OR: 37.13; CI: 6.31 to 218.59, p < 0.01). No significant differences were observed between the groups in terms of periprocedural complications or complete resolution of symptoms.

Conclusion: Surgical treatment for CCJ-DAVFs achieves higher rates of complete obliteration with lower retreatment rates compared to endovascular treatment. However, endovascular treatment showed a tendency towards reducing periprocedural complications while increasing the likelihood of complete resolution of symptoms. Individualized treatment plans for CCJ-DAVFs, should be considered according to their anatomical location and potential surgical accessibility. Further studies are required to confirm these findings.

{"title":"Comparative outcomes of endovascular vs. surgical treatment in craniocervical junction dural arteriovenous fistulas: A systematic review and meta-analysis.","authors":"Basel Musmar, Joanna M Roy, Atakan Orscelik, Sravanthi Koduri, Spyridon Karadimas, Saman Sizdahkhani, Elias Atallah, Stavropoula I Tjoumakaris, Michael Reid Gooch, Hekmat Zarzour, Ritam Ghosh, Richard F Schmidt, Robert H Rosenwasser, Pascal Jabbour","doi":"10.1016/j.jns.2025.123402","DOIUrl":"https://doi.org/10.1016/j.jns.2025.123402","url":null,"abstract":"<p><strong>Background: </strong>Craniocervical junction dural arteriovenous fistulas (CCJ-DAVFs) are rare and complex vascular malformations that are challenging to diagnose and treat. This study aims to compare surgical and endovascular treatments for CCJ-DAVFs through a systematic review and meta-analysis.</p><p><strong>Methods: </strong>A systematic review and meta-analysis was conducted according to the PRISMA guidelines. PubMed, Scopus, and Web of Science databases were searched from inception to July 2024.</p><p><strong>Results: </strong>Fifteen studies involving 266 patients were included. Of these, 143 (53.8 %) patients underwent surgical treatment alone and 123 (46.2 %) underwent endovascular treatment alone. In the surgical group, the complete obliteration rate at last follow-up was 89.8 %. Retreatment rate was 6.2 %. Periprocedural complications occurred in 21.6 % of cases. In the endovascular group, the complete occlusion rate at last follow-up was 73.6 %. Retreatment rate was 46.7 %. Periprocedural complications occurred in 18.8 % of cases. Comparative meta-analysis revealed that the rate of complete obliteration at last follow-up was significantly higher in the surgical group (OR: 0.24; CI: 0.07 to 0.89, p = 0.03). Surgical treatment had a significantly higher successful treatment rate (OR: 0.24; CI: 0.07 to 0.89, p = 0.03) and lower retreatment rate (OR: 37.13; CI: 6.31 to 218.59, p < 0.01). No significant differences were observed between the groups in terms of periprocedural complications or complete resolution of symptoms.</p><p><strong>Conclusion: </strong>Surgical treatment for CCJ-DAVFs achieves higher rates of complete obliteration with lower retreatment rates compared to endovascular treatment. However, endovascular treatment showed a tendency towards reducing periprocedural complications while increasing the likelihood of complete resolution of symptoms. Individualized treatment plans for CCJ-DAVFs, should be considered according to their anatomical location and potential surgical accessibility. Further studies are required to confirm these findings.</p>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"470 ","pages":"123402"},"PeriodicalIF":3.6,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High prevalence of facioscapulohumeral muscular dystrophy (FSHD) and inflammatory myopathies association: Is there an interplay?
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-21 DOI: 10.1016/j.jns.2025.123400
Antonio Lauletta, Yves Allenbach, Anthony Béhin, Teresinha Evangelista, Sarah Léonard-Louis, Matteo Garibaldi, Olivier Benveniste

Introduction: Certain types of muscular dystrophy (MD), notably facioscapulohumeral muscular dystrophy (FSHD), exhibit muscle fiber necrosis with regeneration and a nonspecific inflammatory process. Although rare, the coexistence of MDs and autoimmune myositis has been observed. We hypothesized that, in some circumstances, FSHD may predispose individuals to myositis through muscle damage-induced autoantigen overexpression, contributing to an autoimmune response.

Methods: We conducted a retrospective analysis of patient data from neuromuscular disease centers in France and Italy between September 2012 and May 2024. Clinical, immunological, and myopathological features of 1750 myositis patients were comprehensively reviewed.

Results: Five patients were identified with both FSHD and IIM. Two patients were first diagnosed with FSHD and later developed IIM, while two others initially had IIM followed by an FSHD diagnosis. The fifth patient received simultaneous diagnoses of both conditions. The prevalence of FSHD in the IIM cohort was 1/350, and the prevalence of IIM in the FSHD cohort was 1/40 (p < 0.0001).

Discussion: Our study showed a high prevalence of FSHD and IIM association compared to the general population, with underlying mechanisms that remain unclear. This association might be more frequent than previously reported, indicating a need for increased clinical awareness. Understanding the interplay between FSHD and autoimmune myositis could reveal insights into the immunopathological processes of these diseases and improve diagnostic and therapeutic approaches.

{"title":"High prevalence of facioscapulohumeral muscular dystrophy (FSHD) and inflammatory myopathies association: Is there an interplay?","authors":"Antonio Lauletta, Yves Allenbach, Anthony Béhin, Teresinha Evangelista, Sarah Léonard-Louis, Matteo Garibaldi, Olivier Benveniste","doi":"10.1016/j.jns.2025.123400","DOIUrl":"https://doi.org/10.1016/j.jns.2025.123400","url":null,"abstract":"<p><strong>Introduction: </strong>Certain types of muscular dystrophy (MD), notably facioscapulohumeral muscular dystrophy (FSHD), exhibit muscle fiber necrosis with regeneration and a nonspecific inflammatory process. Although rare, the coexistence of MDs and autoimmune myositis has been observed. We hypothesized that, in some circumstances, FSHD may predispose individuals to myositis through muscle damage-induced autoantigen overexpression, contributing to an autoimmune response.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patient data from neuromuscular disease centers in France and Italy between September 2012 and May 2024. Clinical, immunological, and myopathological features of 1750 myositis patients were comprehensively reviewed.</p><p><strong>Results: </strong>Five patients were identified with both FSHD and IIM. Two patients were first diagnosed with FSHD and later developed IIM, while two others initially had IIM followed by an FSHD diagnosis. The fifth patient received simultaneous diagnoses of both conditions. The prevalence of FSHD in the IIM cohort was 1/350, and the prevalence of IIM in the FSHD cohort was 1/40 (p < 0.0001).</p><p><strong>Discussion: </strong>Our study showed a high prevalence of FSHD and IIM association compared to the general population, with underlying mechanisms that remain unclear. This association might be more frequent than previously reported, indicating a need for increased clinical awareness. Understanding the interplay between FSHD and autoimmune myositis could reveal insights into the immunopathological processes of these diseases and improve diagnostic and therapeutic approaches.</p>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"470 ","pages":"123400"},"PeriodicalIF":3.6,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143039676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mood disorders in patients with motor neuron disease and frontotemporal symptoms: Validation of the Hospital Anxiety and Depression Scale for use in motor neuron disease.
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-17 DOI: 10.1016/j.jns.2024.123378
Veronica Faltracco, Debora Pain, Eleonora Dalla Bella, Nilo Riva, Alessandra Telesca, Elisabetta Soldini, Giulia Gandini, Alice Radici, Barbara Poletti, Giuseppe Lauria, Monica Consonni

Background: Motor neuron disease (MND) is a heterogeneous neurodegenerative disorder, with nearly 50 % of patients exhibiting cognitive and behavioral symptoms in addition to motor decline. Anxiety and depression, though frequently observed in this population, have been understudied in relation to motor and extra-motor profiles.

Objectives: Our study addresses this gap by validating the Hospital Anxiety and Depression Scale for Motor Neuron Disease (HADS-MND) and investigating the interplay between mood, clincial, and frontotemporal symptoms in a large sample of MND patients.

Methods: A total of 249 MND patients underwent clinical, genetic, and neuropsychological assessments. The validity, reliability, sensitivity, and specificity of the HADS-MND global score and subscores were explored. Correlation analyses and group comparisons tested the link between mood, motor and extra-motor profiles.

Results: The bidirectional structure of the HADS-MND was confirmed, but receiver operating characteristics analysis suggests caution for clinical use of the anxiety and depression subscales. The global HADS-MND score is recommended as a measure of psychological distress, with a cut-off point of 10 detecting 38 % of patients with altered scores. Moderate symptoms of anxiety and depression were present in 14 % and 11 % of cases, respectively. Depressive mood was higher in women, patients with frontotemporal symptoms, and severe motor-functional disabilities. Depressive and/or anxiety symptoms were linked to loneliness, behavioral changes, emotional dysregulation, and poor quality of life. Cognitive efficiency was not associated with mood.

Conclusion: Mood disorders appeared independent of cognitive profiles but related to behavioral changes. This is particularly relevant for clinicians discussing end-of-life decisions with patients.

{"title":"Mood disorders in patients with motor neuron disease and frontotemporal symptoms: Validation of the Hospital Anxiety and Depression Scale for use in motor neuron disease.","authors":"Veronica Faltracco, Debora Pain, Eleonora Dalla Bella, Nilo Riva, Alessandra Telesca, Elisabetta Soldini, Giulia Gandini, Alice Radici, Barbara Poletti, Giuseppe Lauria, Monica Consonni","doi":"10.1016/j.jns.2024.123378","DOIUrl":"https://doi.org/10.1016/j.jns.2024.123378","url":null,"abstract":"<p><strong>Background: </strong>Motor neuron disease (MND) is a heterogeneous neurodegenerative disorder, with nearly 50 % of patients exhibiting cognitive and behavioral symptoms in addition to motor decline. Anxiety and depression, though frequently observed in this population, have been understudied in relation to motor and extra-motor profiles.</p><p><strong>Objectives: </strong>Our study addresses this gap by validating the Hospital Anxiety and Depression Scale for Motor Neuron Disease (HADS-MND) and investigating the interplay between mood, clincial, and frontotemporal symptoms in a large sample of MND patients.</p><p><strong>Methods: </strong>A total of 249 MND patients underwent clinical, genetic, and neuropsychological assessments. The validity, reliability, sensitivity, and specificity of the HADS-MND global score and subscores were explored. Correlation analyses and group comparisons tested the link between mood, motor and extra-motor profiles.</p><p><strong>Results: </strong>The bidirectional structure of the HADS-MND was confirmed, but receiver operating characteristics analysis suggests caution for clinical use of the anxiety and depression subscales. The global HADS-MND score is recommended as a measure of psychological distress, with a cut-off point of 10 detecting 38 % of patients with altered scores. Moderate symptoms of anxiety and depression were present in 14 % and 11 % of cases, respectively. Depressive mood was higher in women, patients with frontotemporal symptoms, and severe motor-functional disabilities. Depressive and/or anxiety symptoms were linked to loneliness, behavioral changes, emotional dysregulation, and poor quality of life. Cognitive efficiency was not associated with mood.</p><p><strong>Conclusion: </strong>Mood disorders appeared independent of cognitive profiles but related to behavioral changes. This is particularly relevant for clinicians discussing end-of-life decisions with patients.</p>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"469 ","pages":"123378"},"PeriodicalIF":3.6,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Charcot-Marie-tooth disease type 1 phenotype in a family with a novel myelin protein zero variant.
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-17 DOI: 10.1016/j.jns.2025.123396
Maria Moschou, Vasiliki Poulidou, Eleni Liouta, Georgia Pepe, Vasileios K Kimiskidis, Marianthi Arnaoutoglou
{"title":"Charcot-Marie-tooth disease type 1 phenotype in a family with a novel myelin protein zero variant.","authors":"Maria Moschou, Vasiliki Poulidou, Eleni Liouta, Georgia Pepe, Vasileios K Kimiskidis, Marianthi Arnaoutoglou","doi":"10.1016/j.jns.2025.123396","DOIUrl":"https://doi.org/10.1016/j.jns.2025.123396","url":null,"abstract":"","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"469 ","pages":"123396"},"PeriodicalIF":3.6,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain health: Pathway to primary prevention of neurodegenerative disorders of environmental origin. 大脑健康:环境引起的神经退行性疾病一级预防之路。
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-15 Epub Date: 2024-12-09 DOI: 10.1016/j.jns.2024.123340
Peter S Spencer, Shala-Ghaderi Berntsson, Alain Buguet, Patricia Butterfield, Donald B Calne, Susan M Calne, Santiago Giménez-Roldán, Jacques Hugon, Sahiba Kahlon, Glen E Kisby, Emmeline Lagrange, Anne-Marie E Landtblom, Albert C Ludolph, Peter B Nunn, Valerie S Palmer, Jacques Reis, Gustavo C Román, Jussi O T Sipilä, Scott S Spencer, Raquel Valdes Angues, Jean-Paul Vernoux, Momoko Yabushita

While rising global rates of neurodegenerative disease encourage early diagnosis and therapeutic intervention to block clinical expression (secondary prevention), a more powerful approach is to identify and remove environmental factors that trigger long-latencybrain disease (primary prevention) by acting on a susceptible genotype or acting alone. The latter is illustrated by the post-World War II decline and disappearance of Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex (ALS/PDC), a prototypical often-familial neurodegenerative disease formerly present in very high incidence on the island of Guam. Lessons learned from 75 years of investigation on the etiology of ALS/PDC include: the importance of focusing field research on the disease epicenter and patients with early-onset disease; soliciting exposure history from patients, family, and community to guide multidisciplinary biomedical investigation; recognition that disease phenotype may vary with exposure history, and that familial brain disease may have a primarily environmental origin. Furthermore, removal from exposure to the environmental trigger effects primary disease prevention.

虽然不断上升的全球神经退行性疾病发病率鼓励早期诊断和治疗干预以阻止临床表达(二级预防),但更有效的方法是通过作用于易感基因型或单独作用来识别和消除触发长潜伏期脑疾病的环境因素(一级预防)。第二次世界大战后肌萎缩侧索硬化症和帕金森氏症-痴呆症复合体(ALS/PDC)的减少和消失说明了后者,ALS/PDC是一种典型的家族性神经退行性疾病,以前在关岛发病率很高。75年来对ALS/PDC病因学研究的经验教训包括:将实地研究重点放在疾病中心和早发性疾病患者上的重要性;收集患者、家属和社区的暴露史,指导多学科生物医学调查;认识到疾病表型可能随暴露史而变化,家族性脑疾病可能主要有环境起源。此外,避免暴露于环境触发因素影响初级疾病预防。
{"title":"Brain health: Pathway to primary prevention of neurodegenerative disorders of environmental origin.","authors":"Peter S Spencer, Shala-Ghaderi Berntsson, Alain Buguet, Patricia Butterfield, Donald B Calne, Susan M Calne, Santiago Giménez-Roldán, Jacques Hugon, Sahiba Kahlon, Glen E Kisby, Emmeline Lagrange, Anne-Marie E Landtblom, Albert C Ludolph, Peter B Nunn, Valerie S Palmer, Jacques Reis, Gustavo C Román, Jussi O T Sipilä, Scott S Spencer, Raquel Valdes Angues, Jean-Paul Vernoux, Momoko Yabushita","doi":"10.1016/j.jns.2024.123340","DOIUrl":"10.1016/j.jns.2024.123340","url":null,"abstract":"<p><p>While rising global rates of neurodegenerative disease encourage early diagnosis and therapeutic intervention to block clinical expression (secondary prevention), a more powerful approach is to identify and remove environmental factors that trigger long-latencybrain disease (primary prevention) by acting on a susceptible genotype or acting alone. The latter is illustrated by the post-World War II decline and disappearance of Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex (ALS/PDC), a prototypical often-familial neurodegenerative disease formerly present in very high incidence on the island of Guam. Lessons learned from 75 years of investigation on the etiology of ALS/PDC include: the importance of focusing field research on the disease epicenter and patients with early-onset disease; soliciting exposure history from patients, family, and community to guide multidisciplinary biomedical investigation; recognition that disease phenotype may vary with exposure history, and that familial brain disease may have a primarily environmental origin. Furthermore, removal from exposure to the environmental trigger effects primary disease prevention.</p>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"468 ","pages":"123340"},"PeriodicalIF":3.6,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142818523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the intersection between orthostatic hypotension and daytime sleepiness in Parkinson's disease. 探讨帕金森病患者体位性低血压与日间嗜睡的关系。
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-15 Epub Date: 2024-12-24 DOI: 10.1016/j.jns.2024.123366
Abhimanyu Mahajan, Kevin R Duque, Alok K Dwivedi, Jesus Abanto, Luca Marsili, Emily J Hill, Ameya Saraf, Kelsey J McDonald, Adebukunola Arowosegbe, Heba A Deraz, Aaron Bloemer, Alberto J Espay

Introduction: Daytime sleepiness, reported in about 50 % of patients with Parkinson's disease (PD), is associated with high morbidity, poor quality of life and increased risk for accidents. While an association between dysautonomia and daytime sleepiness in early, de-novo PD has been reported, our understanding of the role of medications, cognitive status and co-morbidites on this relationship is inadequate.

Methods: Data were analyzed from the prospective Cincinnati Cohort Biomarkers Program. The primary outcome of interest was excessive daytime sleepiness (EDS), as measured by the Epworth Sleepiness Scale (ESS; ESS score > 10). The primary exposure variable was orthostatic hypotension (OH). Linear and logistic regression analyses followed by moderated graphical network analyses were conducted to explore the complex association between OH and ESS. Edge weight from graphical network analysis indicates the strength of the association.

Results: Data on 453 subjects with PD were analyzed. Median disease duration was 5.8 years and nearly 90 % were H&Y stage <3. OH was not associated with EDS. OH was associated with depression (edge weight, 0.22) in cognitively impaired patients but not in cognitively normal patients. In addition, depression was associated with ESS (edge weight, 0.37; moderation weight, 0.22) in cognitively impaired patients to a greater extent than in cognitively normal patients (edge weight, 0.22).

Conclusions: OH is not directly associated with daytime sleepiness in early, treated PD. However, OH seems to be associated with ESS via depression in cognitively impaired patients. This complex relationship deserves additional study.

据报道,约50%的帕金森病(PD)患者白天嗜睡与高发病率、生活质量差和事故风险增加有关。虽然已经报道了自主神经异常与早期PD患者日间嗜睡之间的联系,但我们对药物、认知状态和合并症在这种关系中的作用的理解还不充分。方法:数据分析来自前瞻性辛辛那提队列生物标志物项目。主要结局是白天过度嗜睡(EDS),用Epworth嗜睡量表(ESS;ESS评分bbbb10)。主要暴露变量为直立性低血压(OH)。通过线性和逻辑回归分析以及有调节的图形网络分析来探索OH与ESS之间的复杂关系。图网络分析的边权值表示关联的强度。结果:对453例PD患者资料进行分析。中位病程为5.8年,近90%为H&Y期。结论:在早期治疗的PD患者中,OH与日间嗜睡无直接关系。然而,在认知障碍患者中,OH似乎通过抑郁与ESS相关。这种复杂的关系值得进一步研究。
{"title":"Exploring the intersection between orthostatic hypotension and daytime sleepiness in Parkinson's disease.","authors":"Abhimanyu Mahajan, Kevin R Duque, Alok K Dwivedi, Jesus Abanto, Luca Marsili, Emily J Hill, Ameya Saraf, Kelsey J McDonald, Adebukunola Arowosegbe, Heba A Deraz, Aaron Bloemer, Alberto J Espay","doi":"10.1016/j.jns.2024.123366","DOIUrl":"10.1016/j.jns.2024.123366","url":null,"abstract":"<p><strong>Introduction: </strong>Daytime sleepiness, reported in about 50 % of patients with Parkinson's disease (PD), is associated with high morbidity, poor quality of life and increased risk for accidents. While an association between dysautonomia and daytime sleepiness in early, de-novo PD has been reported, our understanding of the role of medications, cognitive status and co-morbidites on this relationship is inadequate.</p><p><strong>Methods: </strong>Data were analyzed from the prospective Cincinnati Cohort Biomarkers Program. The primary outcome of interest was excessive daytime sleepiness (EDS), as measured by the Epworth Sleepiness Scale (ESS; ESS score > 10). The primary exposure variable was orthostatic hypotension (OH). Linear and logistic regression analyses followed by moderated graphical network analyses were conducted to explore the complex association between OH and ESS. Edge weight from graphical network analysis indicates the strength of the association.</p><p><strong>Results: </strong>Data on 453 subjects with PD were analyzed. Median disease duration was 5.8 years and nearly 90 % were H&Y stage <3. OH was not associated with EDS. OH was associated with depression (edge weight, 0.22) in cognitively impaired patients but not in cognitively normal patients. In addition, depression was associated with ESS (edge weight, 0.37; moderation weight, 0.22) in cognitively impaired patients to a greater extent than in cognitively normal patients (edge weight, 0.22).</p><p><strong>Conclusions: </strong>OH is not directly associated with daytime sleepiness in early, treated PD. However, OH seems to be associated with ESS via depression in cognitively impaired patients. This complex relationship deserves additional study.</p>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"468 ","pages":"123366"},"PeriodicalIF":3.6,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Qualitative and quantitative relationships between comorbid seizures and dementia among hospitalized stroke patients. 住院脑卒中患者共病发作与痴呆的定性和定量关系
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-15 Epub Date: 2024-12-16 DOI: 10.1016/j.jns.2024.123332
Mariana Dejuk, Alain Lekoubou, Satvir Saggi, Ankita Agrawal, Leonardo Bonilha, Vernon M Chinchilli, Bruce Ovbiagele

This study examines the relationship between comorbid seizures and dementia among stroke patients using the 2017 Nationwide Inpatient Sample (NIS), the largest publicly available inpatient healthcare database in the United States. We analyzed data from 128,341 stroke patients, including those with ischemic and hemorrhagic strokes, to determine the prevalence of seizures and dementia, and the association between these conditions. Our findings reveal that 7.58 % of stroke patients experienced seizures, while 12.2 % had dementia. Logistic regression analysis demonstrated that stroke patients with seizures had significantly higher odds of also having dementia (OR: 2.08, 95 % CI: 1.95-2.21), with similar trends observed across stroke subtypes. Specifically, the association was strongest among ischemic stroke patients (OR: 2.38, 95 % CI: 2.21-2.56). These results suggest a critical link between seizures and cognitive decline in stroke survivors, underscoring the need for integrated management strategies that address both neurological and cognitive health. Future research should explore the underlying mechanisms and potential therapeutic interventions to mitigate the risk of dementia in stroke patients with seizures.

本研究利用美国最大的公开住院医疗数据库——2017年全国住院患者样本(NIS),研究了卒中患者共病性癫痫发作与痴呆之间的关系。我们分析了128,341名中风患者的数据,包括缺血性和出血性中风,以确定癫痫和痴呆的患病率,以及这些疾病之间的关系。我们的研究结果显示,7.58%的中风患者经历过癫痫发作,而12.2%的中风患者患有痴呆症。Logistic回归分析表明,癫痫发作的卒中患者同时患痴呆的几率明显更高(OR: 2.08, 95% CI: 1.95-2.21),在卒中亚型中也观察到类似的趋势。具体来说,缺血性脑卒中患者的相关性最强(OR: 2.38, 95% CI: 2.21-2.56)。这些结果表明癫痫发作与中风幸存者认知能力下降之间存在重要联系,强调需要同时解决神经和认知健康的综合管理策略。未来的研究应该探索潜在的机制和潜在的治疗干预措施,以减轻癫痫发作的脑卒中患者痴呆的风险。
{"title":"Qualitative and quantitative relationships between comorbid seizures and dementia among hospitalized stroke patients.","authors":"Mariana Dejuk, Alain Lekoubou, Satvir Saggi, Ankita Agrawal, Leonardo Bonilha, Vernon M Chinchilli, Bruce Ovbiagele","doi":"10.1016/j.jns.2024.123332","DOIUrl":"10.1016/j.jns.2024.123332","url":null,"abstract":"<p><p>This study examines the relationship between comorbid seizures and dementia among stroke patients using the 2017 Nationwide Inpatient Sample (NIS), the largest publicly available inpatient healthcare database in the United States. We analyzed data from 128,341 stroke patients, including those with ischemic and hemorrhagic strokes, to determine the prevalence of seizures and dementia, and the association between these conditions. Our findings reveal that 7.58 % of stroke patients experienced seizures, while 12.2 % had dementia. Logistic regression analysis demonstrated that stroke patients with seizures had significantly higher odds of also having dementia (OR: 2.08, 95 % CI: 1.95-2.21), with similar trends observed across stroke subtypes. Specifically, the association was strongest among ischemic stroke patients (OR: 2.38, 95 % CI: 2.21-2.56). These results suggest a critical link between seizures and cognitive decline in stroke survivors, underscoring the need for integrated management strategies that address both neurological and cognitive health. Future research should explore the underlying mechanisms and potential therapeutic interventions to mitigate the risk of dementia in stroke patients with seizures.</p>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"468 ","pages":"123332"},"PeriodicalIF":3.6,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unresolved issues with efgartigimod in CIDP, and broader concerns for future trial design. 在CIDP中未解决的efgartigimod问题,以及对未来试验设计的更广泛关注。
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-15 Epub Date: 2024-12-17 DOI: 10.1016/j.jns.2024.123355
Jonathan Katz, Liberty Jenkins, David Saperstein
{"title":"Unresolved issues with efgartigimod in CIDP, and broader concerns for future trial design.","authors":"Jonathan Katz, Liberty Jenkins, David Saperstein","doi":"10.1016/j.jns.2024.123355","DOIUrl":"10.1016/j.jns.2024.123355","url":null,"abstract":"","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"468 ","pages":"123355"},"PeriodicalIF":3.6,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the switch from IVIG to FcRn inhibition in CIDP: Clinical insights. 在CIDP中从IVIG到FcRn抑制的转换:临床见解。
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-15 Epub Date: 2024-12-16 DOI: 10.1016/j.jns.2024.123354
Chafic Karam
{"title":"Navigating the switch from IVIG to FcRn inhibition in CIDP: Clinical insights.","authors":"Chafic Karam","doi":"10.1016/j.jns.2024.123354","DOIUrl":"10.1016/j.jns.2024.123354","url":null,"abstract":"","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"468 ","pages":"123354"},"PeriodicalIF":3.6,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency of subclavian steal syndrome in a sample of non-Western population. 锁骨下窃血综合征在非西方人群中的发病率。
IF 3.6 3区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2025-01-15 Epub Date: 2024-12-15 DOI: 10.1016/j.jns.2024.123353
Ahmed Elhfnawy, Hazem Abdelkhalek, Alaa Elkordy

Background: Subclavian steal syndrome (SSS) is not rarely found during ultrasound examinations. Previous reports demonstrated a relation between ethnic factors and SSS. Data regarding SSS in non-Western population are still lacking. We aimed to investigate the frequency of SSS in a sample of Egyptian population.

Methods: In a single-center observational study, we conducted a retrospective analysis of successive patients with competent ultrasound examinations of the brain supplying vessels. The patients presented to our neurovascular laboratory in the context of routine clinical practice.

Results: We enrolled 514 patients in our study. SSS was detected in 9 patients (1.8 %) with a median (IQR) age of 58 (56-63) years. One patient with second-degree SSS received a subclavian stent. Among patients with SSS, 4 patients (44.4 %) had carotid atherosclerosis, 4 patients (44.4 %) had ischemic vascular events in the posterior circulation, and two (22.2 %) had hemodynamically significant carotid stenosis ≥50 %. Using a ROC curve, an interarm SBP (systolic blood pressure) difference of ≥10 mmHg had a sensitivity of 77.8 % and specificity of 66 %, whereas a difference of ≥20 mmHg was associated with a sensitivity of 55.6 % and specificity of 92.4 % for SSS (AUC 0.79, 95 % CI 0.6-0.97, p = 0.004).

Conclusions: SSS is not rare among Egyptian population and should be in mind during ultrasound examination, especially for patient with ischemic events in the posterior circulation and those with significant interarm SBP difference.

背景:锁骨下窃血综合征(SSS)在超声检查中并不罕见。以往的报道证实了种族因素与SSS之间的关系。关于非西方人口SSS的数据仍然缺乏。我们的目的是调查SSS在埃及人群样本中的频率。方法:在一项单中心观察性研究中,我们对连续接受脑供血血管超声检查的患者进行了回顾性分析。在常规临床实践的背景下,患者来到我们的神经血管实验室。结果:我们入组了514例患者。9例(1.8%)患者检测到SSS,中位(IQR)年龄为58(56-63)岁。一名二度SSS患者接受了锁骨下支架。SSS患者中,颈动脉粥样硬化4例(44.4%),后循环缺血性血管事件4例(44.4%),颈动脉血流动力学显著狭窄≥50% 2例(22.2%)。ROC曲线显示,收缩压臂间差异≥10 mmHg对SSS的敏感性为77.8%,特异性为66%,而差异≥20 mmHg对SSS的敏感性为55.6%,特异性为92.4% (AUC 0.79, 95% CI 0.6-0.97, p = 0.004)。结论:SSS在埃及人群中并不罕见,超声检查时应注意,特别是后循环缺血事件和臂间收缩压明显差异的患者。
{"title":"Frequency of subclavian steal syndrome in a sample of non-Western population.","authors":"Ahmed Elhfnawy, Hazem Abdelkhalek, Alaa Elkordy","doi":"10.1016/j.jns.2024.123353","DOIUrl":"10.1016/j.jns.2024.123353","url":null,"abstract":"<p><strong>Background: </strong>Subclavian steal syndrome (SSS) is not rarely found during ultrasound examinations. Previous reports demonstrated a relation between ethnic factors and SSS. Data regarding SSS in non-Western population are still lacking. We aimed to investigate the frequency of SSS in a sample of Egyptian population.</p><p><strong>Methods: </strong>In a single-center observational study, we conducted a retrospective analysis of successive patients with competent ultrasound examinations of the brain supplying vessels. The patients presented to our neurovascular laboratory in the context of routine clinical practice.</p><p><strong>Results: </strong>We enrolled 514 patients in our study. SSS was detected in 9 patients (1.8 %) with a median (IQR) age of 58 (56-63) years. One patient with second-degree SSS received a subclavian stent. Among patients with SSS, 4 patients (44.4 %) had carotid atherosclerosis, 4 patients (44.4 %) had ischemic vascular events in the posterior circulation, and two (22.2 %) had hemodynamically significant carotid stenosis ≥50 %. Using a ROC curve, an interarm SBP (systolic blood pressure) difference of ≥10 mmHg had a sensitivity of 77.8 % and specificity of 66 %, whereas a difference of ≥20 mmHg was associated with a sensitivity of 55.6 % and specificity of 92.4 % for SSS (AUC 0.79, 95 % CI 0.6-0.97, p = 0.004).</p><p><strong>Conclusions: </strong>SSS is not rare among Egyptian population and should be in mind during ultrasound examination, especially for patient with ischemic events in the posterior circulation and those with significant interarm SBP difference.</p>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"468 ","pages":"123353"},"PeriodicalIF":3.6,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the Neurological Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1